Table 3.
Outcome analysis partitioning follow up during the first 12 months and beyond, showing adjusted hazard ratios with 95% confidence intervals.
| Outcomes | Adjusted Hazard Ratio (95%CI) |
|||||
|---|---|---|---|---|---|---|
| Primary cohort (n = 147,675) | Secondary cohort (n = 62,122) | |||||
| CKD progression | Full follow up | First 12 months | Beyond first 12 months | Full follow up | First 12 months | Beyond first 12 months |
| No stress related disorders | Ref | Ref | Ref | Ref | Ref | Ref |
| Stress related disorders | 1.23 (1.10-1.37) | 1.11 (0.91-1.36) | 1.29 (1.13-1.48) | 1.63 (1.29-2.06) | 1.16 (0.77-1.74) | 1.94 (1.44-2.63) |
| AKI | Full follow up | First 12 months | Beyond first 12 months | Full follow up | First 12 months | Beyond first 12 months |
| No stress related disorders | Ref | Ref | Ref | Ref | Ref | Ref |
| Stress related disorders | 1.22 (1.04-1.42) | 1.32 (1.04-1.68) | 1.14 (0.93-1.40) | 2.05 (1.47-2.84) | 3.55 (2.05-6.13) | 1.32 (0.83-2.13) |
| AKI defined solely by hospitalization/death diagnosis | Full follow up | First 12 months | Beyond first 12 months | Full follow up | First 12 months | Beyond first 12 months |
| No stress related disorders | Ref | Ref | Ref | Ref | Ref | Ref |
| Stress related disorders | 1.12 (0.88-1.42) | 1.54 (1.03-2.30) | 0.91 (0.67-1.23) | 1.34 (0.77-2.31) | 2.32 (0.53-10.13) | 0.84 (0.41-1.71) |
AKI, acute kidney injury; CI, confidence interval; HR, hazard ratio.
In the primary cohort, baseline eGFR is defined as the average of all measurements 1-12 months before index date; In the secondary cohort, baseline eGFR is defined as the average of all measurements 6-12 months before index date.
Conditional Cox models were stratified by matching identifiers (birth year, sex, eGFR categories) and adjusted for eGFR (continuous), history of severe somatic disease (history of other psychiatric disorders, history of acute kidney injury, hypertension, diabetes mellitus, cancer, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, rheumatic disease, peptic ulcer disease) and ongoing medications (aspirin/NSAIDs, ACEi/ARBs, MRA, beta blockers, other diuretics, calcium channel blockers, other blood pressure medications, selective serotonin reuptake inhibitors and lithium).